Literature DB >> 9030361

Prevention of simian immunodeficiency virus, SIVsm, or HIV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005.

D Böttiger1, N G Johansson, B Samuelsson, H Zhang, P Putkonen, L Vrang, B Oberg.   

Abstract

OBJECTIVE: To study the possibilities and limitations of postexposure treatment to prevent the establishment of infection after accidental exposure to HIV. DESIGN AND METHODS: The effect of 2,3'-dideoxy-3'-hydroxymethyl cytidine (B1 A-005) was investigated on acute simian immunodeficiency virus (SIV) and HIV-2 infections in macaques in pre- and postexposure treatment experiments.
RESULTS: Postexposure treatment with BLA-005 (3 x 10 mg/kg) for as short as 3 days prevented infection with SIVsm after intravenous or rectal inoculation. Infection with HIV-2 could also be blocked by postexposure BFA-005 treatment.
CONCLUSION: This study shows that therapeutic intervention can block early systemic and mucosal infections with SIV and HIV-2. Further evaluation is ongoing.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9030361     DOI: 10.1097/00002030-199702000-00004

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  9 in total

1.  SURGEON AND HIV INFECTION: Post Exposure Prophylaxis: Need of the hour.

Authors:  Man Mohan Harjai; Rohit Sharma; P K Menon; B M Nagpal; Y Singh
Journal:  Med J Armed Forces India       Date:  2017-06-12

2.  Pharmacokinetics and distribution over the blood-brain barrier of zalcitabine (2',3'-dideoxycytidine) and BEA005 (2', 3'-dideoxy-3'-hydroxymethylcytidine) in rats, studied by microdialysis.

Authors:  N Borg; L Ståhle
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

Review 3.  Tolerability of postexposure antiretroviral prophylaxis for occupational exposures to HIV.

Authors:  L M Lee; D K Henderson
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

4.  Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2).

Authors:  R A Otten; D K Smith; D R Adams; J K Pullium; E Jackson; C N Kim; H Jaffe; R Janssen; S Butera; T M Folks
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

5.  Evaluation and treatment of the human immunodeficiency virus-1-exposed infant.

Authors: 
Journal:  Paediatr Child Health       Date:  2004-07       Impact factor: 2.253

Review 6.  Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure.

Authors:  T N Young; F J Arens; G E Kennedy; J W Laurie; G w Rutherford
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

7.  Italian consensus statement on paediatric HIV infection.

Authors:  C Giaquinto; M Penazzato; R Rosso; S Bernardi; O Rampon; P Nasta; A Ammassari; A Antinori; R Badolato; G Castelli Gattinara; A d'Arminio Monforte; M De Martino; A De Rossi; P Di Gregorio; S Esposito; F Fatuzzo; S Fiore; A Franco; C Gabiano; L Galli; O Genovese; V Giacomet; A Giannattasio; C Gotta; A Guarino; A Martino; F Mazzotta; N Principi; M B Regazzi; P Rossi; R Russo; M Saitta; F Salvini; S Trotta; A Viganò; G Zuccotti; G Carosi
Journal:  Infection       Date:  2010-06-01       Impact factor: 7.455

8.  Knowledge, Attitude, and Practice of Postexposure Prophylaxis against HIV Infection among Healthcare Workers in Hiwot Fana Specialized University Hospital, Eastern Ethiopia.

Authors:  Endalkachew Mekonnen Eticha; Ashenafi Beru Gemeda
Journal:  AIDS Res Treat       Date:  2019-02-21

9.  Comparative study of the persistence of anti-HIV activity of deoxynucleoside HIV reverse transcriptase inhibitors after removal from culture.

Authors:  Elijah Paintsil; Susan P Grill; Ginger E Dutschman; Yung-Chi Cheng
Journal:  AIDS Res Ther       Date:  2009-04-22       Impact factor: 2.250

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.